{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:19:02Z","timestamp":1793229542081,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"AstraZeneca Pharmaceuticals LP"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s12325-025-03287-4","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T08:31:12Z","timestamp":1753173072000},"page":"4916-4932","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Bleeding-Related Hospitalizations Among Direct Oral Anticoagulant Users and Nonusers in Medicare Fee-For-Service: Variation in Prevalence, Burden, and Characteristics"],"prefix":"10.1007","volume":"42","author":[{"given":"Carol M.","family":"Bazell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie N.","family":"Alston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Latha G.","family":"Ganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond C.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Andrew","family":"Wilsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie A.","family":"Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winston C.","family":"Fopalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher W.","family":"Baugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"issue":"2","key":"3287_CR1","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1053\/j.gastro.2021.10.017","volume":"162","author":"AF Peery","year":"2022","unstructured":"Peery AF, Crockett SD, Murphy CC, et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2021. Gastroenterology. 2022;162(2):621\u201344.","journal-title":"Gastroenterology"},{"issue":"3","key":"3287_CR2","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1161\/STROKEAHA.121.037332","volume":"53","author":"AT Bako","year":"2022","unstructured":"Bako AT, Pan A, Potter T, et al. Contemporary trends in the nationwide incidence of primary intracerebral hemorrhage. Stroke. 2022;53(3):e70\u20134.","journal-title":"Stroke"},{"issue":"4","key":"3287_CR3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.1190","volume":"1","author":"AB Bambhroliya","year":"2018","unstructured":"Bambhroliya AB, Donnelly JP, Thomas EJ, et al. Estimates and temporal trend for US nationwide 30-day hospital readmission among patients with ischemic and hemorrhagic stroke. JAMA Netw Open. 2018;1(4): e181190.","journal-title":"JAMA Netw Open"},{"issue":"9","key":"3287_CR4","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1182\/blood.2021014766","volume":"142","author":"BS Bannow","year":"2023","unstructured":"Bannow BS, Konkle BA. How I approach bleeding in hospitalized patients. Blood. 2023;142(9):761\u20138.","journal-title":"Blood"},{"issue":"3","key":"3287_CR5","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1161\/CIRCRESAHA.118.313155","volume":"124","author":"NC Chan","year":"2019","unstructured":"Chan NC, Weitz JI. Antithrombotic agents. Circ Res. 2019;124(3):426\u201336.","journal-title":"Circ Res"},{"issue":"1","key":"3287_CR6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1161\/CIRCRESAHA.120.316340","volume":"127","author":"J Kornej","year":"2020","unstructured":"Kornej J, B\u00f6rschel CS, Benjamin EJ, Schnabel RB. Epidemiology of atrial fibrillation in the 21st century: novel methods and new insights. Circ Res. 2020;127(1):4\u201320.","journal-title":"Circ Res"},{"issue":"2","key":"3287_CR7","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1001\/jamacardio.2018.4537","volume":"4","author":"J Gregson","year":"2019","unstructured":"Gregson J, Kaptoge S, Bolton T, et al. Cardiovascular risk factors associated with venous thromboembolism. JAMA Cardiol. 2019;4(2):163\u201373.","journal-title":"JAMA Cardiol"},{"issue":"19","key":"3287_CR8","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","volume":"4","author":"TL Ortel","year":"2020","unstructured":"Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4(19):4693\u2013738.","journal-title":"Blood Adv"},{"issue":"1","key":"3287_CR9","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","volume":"149","author":"JA Joglar","year":"2024","unstructured":"Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(1):e1-156.","journal-title":"Circulation"},{"issue":"22","key":"3287_CR10","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.026723","volume":"11","author":"AM Navar","year":"2022","unstructured":"Navar AM, Kolkailah AA, Overton R, et al. Trends in oral anticoagulant use among 436 864 patients with atrial fibrillation in community practice, 2011 to 2020. J Am Heart Assoc. 2022;11(22):e026723.","journal-title":"J Am Heart Assoc"},{"key":"3287_CR11","unstructured":"US Food and Drug Administration, Center for Drug Evaluation and Research. Pradaxa (dabigatran etexilate mesylate) capsules for oral use. 2010. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/022512s007lbl.pdf. Accessed Sep 2024."},{"key":"3287_CR12","unstructured":"US Food and Drug Administration, Center for Drug Evaluation and Research. Xarelto (rivaroxaban) tablets, for oral use. 2011. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215859s000lbl.pdf. Accessed 12 Sep 2024."},{"key":"3287_CR13","unstructured":"US Food and Drug Administration, Center for Drug Evaluation and Research. Eliquis (apixaban) tablets for oral use. 2012. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/202155s000lbl.pdf. Accessed 12 Sep 2024."},{"key":"3287_CR14","unstructured":"US Food and Drug Administration, Center for Drug Evaluation and Research. Savaysa (edoxaban) tablets for oral use. 2015. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/206316lbl.pdf. Accessed 12 Sep 2024."},{"key":"3287_CR15","unstructured":"US Food and Drug Administration, Center for Drug Evaluation and Research. Bevyxxa (betrixaban) capsules, for oral use. 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208383s000lbl.pdf. Accessed 12 Sep 2024."},{"issue":"13","key":"3287_CR16","doi-asserted-by":"publisher","first-page":"e017559","DOI":"10.1161\/JAHA.120.017559","volume":"9","author":"A Chen","year":"2020","unstructured":"Chen A, Stecker E, Warden B. Direct oral anticoagulant use: a practical guide to common clinical challenges. J Am Heart Assoc. 2020;9(13):e017559.","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"3287_CR17","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation [published correction appears in N Engl J Med. 2010 Nov 4;363(19):1877]. N Engl J Med. 2009;361(12):1139\u201351.","journal-title":"N Engl J Med"},{"issue":"10","key":"3287_CR18","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883\u201391.","journal-title":"N Engl J Med"},{"issue":"11","key":"3287_CR19","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981\u201392.","journal-title":"N Engl J Med"},{"issue":"22","key":"3287_CR20","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093\u2013104.","journal-title":"N Engl J Med"},{"issue":"20","key":"3287_CR21","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1093\/eurheartj\/eht039","volume":"34","author":"SJ Connolly","year":"2013","unstructured":"Connolly SJ, Eikelboom J, Dorian P, et al. Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase\u00a02, randomized, dose-ranging study (Explore-Xa). Eur Heart J. 2013;34(20):1498\u2013505.","journal-title":"Eur Heart J"},{"issue":"7","key":"3287_CR22","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2021.1693","volume":"2","author":"A Troy","year":"2021","unstructured":"Troy A, Anderson TS. National trends in use of and spending on oral anticoagulants among US Medicare beneficiaries from 2011 to 2019. JAMA Health Forum. 2021;2(7): e211693.","journal-title":"JAMA Health Forum"},{"issue":"6","key":"3287_CR23","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1161\/CIRCULATIONAHA.120.050438","volume":"143","author":"DJ Angiolillo","year":"2021","unstructured":"Angiolillo DJ, Bhatt DL, Cannon CP, et al. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a North American perspective: 2021 update. Circulation. 2021;143(6):583\u201396.","journal-title":"Circulation"},{"issue":"26","key":"3287_CR24","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","volume":"363","author":"R Bauersachs","year":"2010","unstructured":"Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499\u2013510.","journal-title":"N Engl J Med"},{"issue":"8","key":"3287_CR25","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1113697","volume":"368","author":"S Schulman","year":"2013","unstructured":"Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368(8):709\u201318.","journal-title":"N Engl J Med"},{"issue":"5","key":"3287_CR26","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jacc.2020.04.053","volume":"76","author":"GF Tomaselli","year":"2020","unstructured":"Tomaselli GF, Mahaffey KW, Cuker A, et al. 2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020;76(5):594\u2013622.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"3287_CR27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5603\/CJ.a2021.0147","volume":"29","author":"K White","year":"2022","unstructured":"White K, Faruqi U, Cohen AAT. New agents for DOAC reversal: a practical management review. Br J Cardiol. 2022;29(1):1.","journal-title":"Br J Cardiol"},{"key":"3287_CR28","unstructured":"US Food and Drug Administration, Center for Drug Evaluation and Research. Praxbind BLA 761025 accelerated approval letter, October 16, 2015. 2015. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/761025Orig1s000Approv.pdf. Accessed 12 Sep 2024."},{"key":"3287_CR29","unstructured":"US Food and Drug Administration, Center for Drug Evaluation and Research. Andexxa BL 125586\/0 accelerated approval, May\u00a03, 2018. 2018. https:\/\/www.fda.gov\/media\/113285\/download. Accessed 12 Sep 2024."},{"issue":"3","key":"3287_CR30","first-page":"27","volume":"29","author":"C Eicheldinger","year":"2008","unstructured":"Eicheldinger C, Bonito A. More accurate racial and ethnic codes for Medicare administrative data. Health Care Financ Rev. 2008;29(3):27\u201342.","journal-title":"Health Care Financ Rev"},{"key":"3287_CR31","unstructured":"Healthcare Cost and Utilization Project, Agency for Healthcare Research and Quality. Elixhauser Comorbidity Software refined for ICD-10-CM. 2024. https:\/\/hcup-us.ahrq.gov\/toolssoftware\/comorbidityicd10\/comorbidity_icd10.jsp. Accessed 12 Sep 2024."},{"key":"3287_CR32","unstructured":"Centers for Medicare and Medicaid Services. Provider of services file - hospital & non-hospital facilities. 2021. https:\/\/data.cms.gov\/provider-characteristics\/hospitals-and-other-facilities\/provider-of-services-file-hospital-non-hospital-facilities\/data\/q4-2021. Accessed 12 Sep 2024."},{"key":"3287_CR33","unstructured":"Centers for Medicare and Medicaid Services. FY 2024 IPPS final rule home page. 2024. https:\/\/www.cms.gov\/medicare\/payment\/prospective-payment-systems\/acute-inpatient-pps\/fy-2024-ipps-final-rule-home-page#Data. Accessed 12 Sep 2024."},{"key":"3287_CR34","unstructured":"Research Data Assistance Center. Provider number table. 2024. https:\/\/resdac.org\/sites\/datadocumentation.resdac.org\/files\/NCH%20Provider%20Number%20Table.txt. Accessed 12 Sep 2024."},{"key":"3287_CR35","unstructured":"Centers for Medicare and Medicaid Services. 2024 condition-specific readmission measures updates and specifications report. 2024. https:\/\/qualitynet.cms.gov\/inpatient\/measures\/readmission\/methodology. Accessed 12 Sep 2024."},{"issue":"13","key":"3287_CR36","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.116.022388","volume":"135","author":"JV Freeman","year":"2017","unstructured":"Freeman JV, Wang Y, Akar J, Desai N, Krumholz H. National trends in atrial fibrillation hospitalization, readmission, and mortality for Medicare beneficiaries, 1999\u20132013. Circulation. 2017;135(13):1227\u201339.","journal-title":"Circulation"},{"issue":"2","key":"3287_CR37","doi-asserted-by":"publisher","first-page":"158.e1","DOI":"10.1016\/j.amjmed.2013.10.005","volume":"127","author":"S Naderi","year":"2014","unstructured":"Naderi S, Wang Y, Miller AL, et al. The impact of age on the epidemiology of atrial fibrillation hospitalizations. Am J Med. 2014;127(2):158.e1-158.e7.","journal-title":"Am J Med"},{"issue":"24","key":"3287_CR38","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","volume":"361","author":"S Schulman","year":"2009","unstructured":"Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342\u201352.","journal-title":"N Engl J Med"},{"issue":"15","key":"3287_CR39","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","volume":"369","author":"HR B\u00fcller","year":"2013","unstructured":"B\u00fcller HR, D\u00e9cousus H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406\u201315.","journal-title":"N Engl J Med"},{"issue":"9","key":"3287_CR40","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1302507","volume":"369","author":"G Agnelli","year":"2013","unstructured":"Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799\u2013808.","journal-title":"N Engl J Med"},{"issue":"12","key":"3287_CR41","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1080\/13696998.2017.1362412","volume":"20","author":"S Deitelzweig","year":"2017","unstructured":"Deitelzweig S, Neuman WR, Lingohr-Smith M, Menges B, Lin J. Incremental economic burden associated with major bleeding among atrial fibrillation patients treated with factor Xa inhibitors. J Med Econ. 2017;20(12):1217\u201323.","journal-title":"J Med Econ"},{"issue":"28","key":"3287_CR42","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1093\/eurheartj\/ehu083","volume":"35","author":"JP Piccini","year":"2014","unstructured":"Piccini JP, Garg J, Patel MR, et al. Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. Eur Heart J. 2014;35(28):1873\u201380.","journal-title":"Eur Heart J"},{"issue":"21","key":"3287_CR43","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1001\/jama.2018.17242","volume":"320","author":"WA Ray","year":"2018","unstructured":"Ray WA, Chung CP, Murray KT, et al. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. JAMA. 2018;320(21):2221\u201330.","journal-title":"JAMA"},{"issue":"8","key":"3287_CR44","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1136\/heartjnl-2021-319332","volume":"108","author":"J Komen","year":"2022","unstructured":"Komen J, Potteg\u00e5rd A, Hjemdahl P, et al. Non-vitamin\u00a0K antagonist oral anticoagulants, proton pump inhibitors, and gastrointestinal bleeds. Heart. 2022;108(8):613\u20138.","journal-title":"Heart"},{"key":"3287_CR45","first-page":"1","volume":"31","author":"MJ Hall","year":"2010","unstructured":"Hall MJ, Marsteller J, Owings M. Factors influencing rural residents\u2019 utilization of urban hospitals. Natl Health Stat Report. 2010;31:1\u201312.","journal-title":"Natl Health Stat Report"},{"issue":"7","key":"3287_CR46","doi-asserted-by":"publisher","first-page":"e282","DOI":"10.1161\/STR.0000000000000407","volume":"53","author":"SM Greenberg","year":"2022","unstructured":"Greenberg SM, Ziai WC, Cordonnier C, et al. 2022 guideline for the management of patients with spontaneous intracerebral hemorrhage: a guideline from the American Heart Association\/American Stroke Association. Stroke. 2022;53(7):e282-361.","journal-title":"Stroke"},{"key":"3287_CR47","doi-asserted-by":"publisher","first-page":"1409713","DOI":"10.3389\/fneur.2024.1409713","volume":"15","author":"RV Patel","year":"2024","unstructured":"Patel RV, Tong L, Molyneaux BJ, et al. Interhospital transfer dynamics for patients with intracranial hemorrhage in Massachusetts. Front Neurol. 2024;15:1409713.","journal-title":"Front Neurol"},{"key":"3287_CR48","volume-title":"An all-payer view of hospital discharge to postacute care, 2013\u2014healthcare cost and utilization project (HCUP) statistical briefs","author":"W Tian","year":"2016","unstructured":"Tian W. An all-payer view of hospital discharge to postacute care, 2013\u2014healthcare cost and utilization project (HCUP) statistical briefs. Rockville: Agency for Healthcare Research and Quality (US); 2016."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03287-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03287-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03287-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T15:09:21Z","timestamp":1758899361000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03287-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":48,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["3287"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03287-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]},"assertion":[{"value":"15 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Carol Bazell, Maggie Alston, Stephanie Leary, and Winston Fopalan are employees of Milliman Inc. and received consulting fees from AstraZeneca. Latha Ganti is a consultant for AstraZeneca. Raymond Chang and H Andrew Wilsey are employees of AstraZeneca Pharmaceuticals LP and own stock in AstraZeneca. Christopher Baugh is a paid speaker for Roche Diagnostics; participated in Roche Advisory Boards; is an advisor to Lucia Health Guidelines, Quai, and Vera Health; serves on advisory boards for Pfizer, Salix Pharmaceuticals, and AstraZeneca; and has received research funding support from Abbott Laboratories, Roche Diagnostics, and Sanofi. AstraZeneca Pharmaceuticals LP produces and markets ANDEXXA (coagulation factor Xa [recombinant], inactivated-zhzo), a drug used for the reversal of anticoagulation in patients treated with apixaban and rivaroxaban. The authors report no other conflicts of interest in this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This manuscript is based on previously collected non-identifiable healthcare administrative claims data and does not contain any new studies with human participants or animals performed by any of the authors. All uses of data in this manuscript fall under Milliman Inc.\u2019s existing data use agreements for the data sources.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}